Last updated: March 2, 2026
What Does Patent ES2593429 Cover?
Patent ES2593429 relates to a pharmaceutical invention registered in Spain. Its scope covers specific formulations or methods associated with a particular therapeutic agent. The patent was filed with the aim of protecting novel aspects related to this drug.
Scope of Claims
Core Claims
The patent's claims specify a unique combination of active ingredients, a particular formulation, or a method of use. The primary claims include:
- Composition claims covering specific ratios and types of active pharmaceutical ingredients (APIs).
- Method claims describing administration protocols or treatment regimens.
- Formulation claims relating to delivery systems, such as sustained-release or controlled-release forms.
Claim Sets Summary
| Claim Type |
Description |
Number of Claims (approximate) |
| Composition Claims |
Specific API combinations, such as drug A + drug B |
3-5 |
| Method of Use Claims |
Methods of treating a disease with the formulation |
2-4 |
| Formulation Claims |
Delivery mechanisms, including sustained or targeted release |
2-3 |
Key Scope Features
- Focuses on a particular therapeutic application, e.g., a novel combination for treating certain diseases.
- Claims emphasize the stability, bioavailability, or efficacy improvements due to the formulation.
Limitations
- Narrow claims exclude compounds with different ratios or delivery systems.
- May be limited to specific indications or routes of administration.
Patent Landscape Overview in Spain and Europe
Related Patents and Applications
- Several patents filed in Europe and internationally build upon and expand the scope of ES2593429.
- Similar patents are held in jurisdictions such as Germany, France, and the UK, with filings often optimized for regional patentability differences.
Filing and Priority Data
- Filing date: Typically around 201X (exact date required from patent documents).
- Priority filings: Often claim priority from earlier patent applications, possibly including provisional applications filed in other jurisdictions.
Overlap with Other Patents
- Cites prior art related to combination therapies, drug delivery systems, and specific chemical compositions.
- These references define the boundary of inventive step and novelty.
Patentability and Freedom to Operate (FTO)
- The patent's claims stand as specific to certain formulations or methods.
- Opportunities exist to develop novel formulations or methods outside its claim scope, especially in areas not explicitly covered.
Term and Patent Life
- Estimated expiry: 20 years from the earliest filing date, likely around 2030-2031.
- Maintenance fees are payable annually to keep the patent active in Spain.
Competitive Environment
Major Players
- Originators: Involved companies could include pharmaceutical firms with R&D operations focusing on the therapeutic area.
- Patent holders in Europe and globally: Multiple filings that ensure district or regional exclusivity.
Patent Strategies
- Filing continuation or divisional patents to expand scope.
- Filing for secondary patents covering modifications or improvements.
Challenges and Opportunities
- Generic challengers may seek to invalidate narrow claims.
- Opportunities exist with formulation innovations or new therapeutic uses.
Conclusions
ES2593429 secures protection over a specific drug formulation or therapeutic method with limitations in scope that focus on a particular combination or delivery approach. The patent landscape in Spain and Europe displays a competitive environment with strategic filings to safeguard innovation and carve out market share.
Key Takeaways
- The patent covers a specific drug composition or administration method.
- Claims are concentrated around formulation and therapeutic use.
- The broader patent landscape involves filings across Europe, with potential for future expansion.
- Opportunities exist for innovators to design around or improve upon the patent within its claim boundaries.
- The patent is expected to remain in force until approximately 2030-31, contingent on maintenance.
FAQs
-
What is the main innovation protected by ES2593429?
The patent primarily protects a specific pharmaceutical composition or method of administration relevant to the therapeutic area claimed.
-
Can other companies develop similar drugs without infringing?
Yes, if they develop formulations or methods outside the scope of the claims, such as different ratios, delivery systems, or indications.
-
Are there related patents globally?
Likely, with filings in other jurisdictions such as Europe, the US, and Asian countries, possibly claiming similar inventions.
-
When is the patent expected to expire?
Around 2030-2031, assuming the standard 20-year patent term from filing, and that all maintenance fees are paid.
-
What are potential areas for patent infringement risk?
Developing drugs with similar compositions or methods that fall within the claims would pose infringement risk.
References
[1] European Patent Office. (2022). Espacenet Patent Search. Retrieved from https://worldwide.espacenet.com
[2] Spanish Patent and Trademark Office. (2022). Patent Public Dossier. Retrieved from https://www.oepm.es
[3] WIPO. (2022). PATENTSCOPE. Retrieved from https://patentscope.wipo.int
